TITLE:
A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis

CONDITION:
Candidiasis, Esophageal

INTERVENTION:
L-743,872

SUMMARY:

      The purpose of this study is to see if it is safe to give L-743,872 to men with candidal
      esophagitis, an AIDS-related yeast infection in the esophagus.
    

DETAILED DESCRIPTION:

      In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of
      three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the
      final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study.
    

ELIGIBILITY:
Gender: Male
Age: 18 Years to 65 Years
Criteria:

        Inclusion Criteria

        You may be eligible for this study if you:

          -  Are an 18- to 65-year-old man with candidal esophagitis.
      
